The main classes of monoclonal antibodies used in severe asthma treatment are anti-IgE (anti-immunoglobulin E) (omalizumab), anti-IL5/anti-IL5R (anti-interleukin 5 or anti-the receptor of interleukin-5) (mepolizumab, reslizumab, and benralizumab), anti-IL4R (anti-the receptor for interleukin 4) (dupilumab), and anti-TSLP (anti-thymic stromal lymphopoietin) (tezepelumab) [11]. This evidence concerns the gene IL4 and asthma.